Chengdu BioAugen Biotechnologies Co., LTD. (BioAugen), established in June 2021, is a subsidiary of 3H Prot BioPharm, Inc. that is registered in the Cayman Islands. BioAugen is situated in Tianfu International Bio-Town of Chengdu Hi-Tech Industrial Development Zone. It is the first high-tech bio-pharma enterprise established in China specialized in developing modernized rabbit mammary gland bioreactor platform (MRPharming™) to produce recombinant proteins, peptides, antibodies, and vaccines for therapeutics, nutritional supplements, and cosmetic ingredients. We are committed to providing high-quality, safe, affordable, and innovative protein drugs and products for patients and customers in China and worldwide.

BioAugen’s MRPharming™ is based on TARGATT™ precision gene editing technology. This cutting-edge proprietary technology was acquired from Applied StemCell Therapeutics, Inc., a well-known gene therapy company that has been operated in the United States for over 15 years. Utilizing this unique technology, we focus on engineering mammary gland bioreactors in rabbits and other farm animals to produce recombinant proteins. Compared to other commonly used bioreactors or fermenters, MRPharming™ is distinctive in rendering the seed animals with higher genetic stability, scalability more flexible, the manufacture process simpler, and investment and cost lower, whereas the products with higher yield, better quality and safety.